AU754943B2 - Benzimidazole analogs as down-regulators of IgE - Google Patents

Benzimidazole analogs as down-regulators of IgE Download PDF

Info

Publication number
AU754943B2
AU754943B2 AU43120/99A AU4312099A AU754943B2 AU 754943 B2 AU754943 B2 AU 754943B2 AU 43120/99 A AU43120/99 A AU 43120/99A AU 4312099 A AU4312099 A AU 4312099A AU 754943 B2 AU754943 B2 AU 754943B2
Authority
AU
Australia
Prior art keywords
substituted
ige
benzimidazole
doc
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU43120/99A
Other languages
English (en)
Other versions
AU4312099A (en
Inventor
Michael G. Campbell
Michael W. Major
Mark L. Richards
Jagadish Sircar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU754943(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of AU4312099A publication Critical patent/AU4312099A/en
Application granted granted Critical
Publication of AU754943B2 publication Critical patent/AU754943B2/en
Priority to AU2003201363A priority Critical patent/AU2003201363B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU43120/99A 1998-05-22 1999-05-21 Benzimidazole analogs as down-regulators of IgE Ceased AU754943B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003201363A AU2003201363B2 (en) 1998-05-22 2003-03-19 Benzimidazole analogs as down-regulators of IgE

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
US60/086494 1998-05-22
PCT/US1999/011490 WO1999061020A1 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003201363A Division AU2003201363B2 (en) 1998-05-22 2003-03-19 Benzimidazole analogs as down-regulators of IgE

Publications (2)

Publication Number Publication Date
AU4312099A AU4312099A (en) 1999-12-13
AU754943B2 true AU754943B2 (en) 2002-11-28

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
AU40942/99A Ceased AU754562B2 (en) 1998-05-22 1999-05-21 Benzimidazole derivatives as modulators of IgE
AU43120/99A Ceased AU754943B2 (en) 1998-05-22 1999-05-21 Benzimidazole analogs as down-regulators of IgE
AU41978/99A Abandoned AU4197899A (en) 1998-05-22 1999-05-21 Compounds having ige affecting properties

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU40942/99A Ceased AU754562B2 (en) 1998-05-22 1999-05-21 Benzimidazole derivatives as modulators of IgE

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU41978/99A Abandoned AU4197899A (en) 1998-05-22 1999-05-21 Compounds having ige affecting properties

Country Status (22)

Country Link
US (2) US6271390B1 (enExample)
EP (3) EP1077700B1 (enExample)
JP (3) JP2002516277A (enExample)
KR (1) KR100591652B1 (enExample)
CN (4) CN1311675A (enExample)
AT (1) ATE292465T1 (enExample)
AU (3) AU754562B2 (enExample)
BR (3) BR9910641A (enExample)
CA (3) CA2332985A1 (enExample)
CZ (2) CZ20004351A3 (enExample)
DE (1) DE69924607T2 (enExample)
ES (1) ES2241285T3 (enExample)
HU (3) HUP0102128A3 (enExample)
IL (3) IL139827A0 (enExample)
MX (3) MXPA00011422A (enExample)
NO (3) NO20005887L (enExample)
NZ (2) NZ508413A (enExample)
PL (3) PL345219A1 (enExample)
RU (2) RU2236221C2 (enExample)
UA (2) UA67775C2 (enExample)
WO (3) WO1999061019A1 (enExample)
ZA (3) ZA200007754B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
HUP0102128A3 (en) * 1998-05-22 2002-05-28 Avanir Pharmaceuticals San Die Mediciaments containing benzimidazole derivatives as modulators of ige
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
BR9913562A (pt) 1998-09-11 2001-05-22 Ajinomoto Kk Derivados de benzeno, inibidor de ativação de ap-1 e nf-capa b, inibidor de produção de citoquina inflamatória, inibidor de produção de metaloprotease matricial ou inibidor de aparecimento de fator de adesão de célula inflamatório, e, agente antiinflamatório, anti-reumático, imunossupressor, inibidor de metástase cancerosa, remédio para arterioesclerose e agente antiviral
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
KR20020015308A (ko) * 1999-03-26 2002-02-27 추후보정 아릴 치환된 피라졸, 이미다졸, 옥사졸, 티아졸 및 피롤,및 이의 용도
JP4609691B2 (ja) * 1999-07-01 2011-01-12 味の素株式会社 複素環化合物及びその医薬用途
AU6866700A (en) 1999-09-01 2001-03-26 Ajinomoto Co., Inc. Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
PT1368028E (pt) 2001-03-12 2007-11-26 Avanir Pharmaceuticals Compostos de benzimidazole para modulação de ige e inibição da proliferação celular
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7271261B2 (en) 2001-10-19 2007-09-18 Ortho-Mcneil Pharmaceutical, Inc. Substituted benzimidazoles and imidazo-[4,5]-pyridines
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003277689A1 (en) * 2002-11-02 2004-06-07 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
EP1613313B1 (en) 2003-04-17 2007-06-06 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-4,5]-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
KR20120091276A (ko) 2004-02-20 2012-08-17 베링거 인겔하임 인터내셔날 게엠베하 바이러스 폴리머라제 억제제
WO2005113489A1 (en) * 2004-05-12 2005-12-01 Proteotech, Inc. Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
CA2572218C (en) 2004-06-30 2013-06-11 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP1954287B2 (en) † 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
SG172353A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
CA2737601C (en) 2009-06-11 2014-10-21 Abbott Laboratories Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
PT2595965T (pt) 2010-07-20 2016-08-22 Vestaron Corp Triazinas e pirimidinas inseticidas
WO2012058254A1 (en) 2010-10-29 2012-05-03 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
JP5789888B2 (ja) 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US11548867B2 (en) 2017-07-19 2023-01-10 Idea Ya Biosciences, Inc. Amido compounds as AhR modulators
EP3852745A4 (en) 2018-09-18 2022-05-04 Terns, Inc. COMPOUNDS FOR TREATMENT OF CERTAIN LEUKEMIA
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700906A1 (en) * 1994-09-02 1996-03-13 Bristol-Myers Squibb Company Heterocyclic derivatives of N-phenylamides
EP0719765A2 (en) * 1994-12-27 1996-07-03 Mitsui Toatsu Chemicals, Inc. Phenylbenzimidazole derivatives
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) * 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DE69113162T2 (de) 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
ES2102036T3 (es) * 1992-06-15 1997-07-16 Celltech Therapeutics Ltd Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv.
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
RU2084451C1 (ru) * 1995-10-17 1997-07-20 Акционерное общество закрытого типа "Алмазный Центр" Способ получения 2-фенилбензимидазола
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
HUP0102128A3 (en) * 1998-05-22 2002-05-28 Avanir Pharmaceuticals San Die Mediciaments containing benzimidazole derivatives as modulators of ige
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
EP1342199A1 (en) * 2000-11-15 2003-09-10 Manugistics Atlanta, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700906A1 (en) * 1994-09-02 1996-03-13 Bristol-Myers Squibb Company Heterocyclic derivatives of N-phenylamides
EP0719765A2 (en) * 1994-12-27 1996-07-03 Mitsui Toatsu Chemicals, Inc. Phenylbenzimidazole derivatives
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions

Also Published As

Publication number Publication date
DE69924607T2 (de) 2006-02-02
PL345952A1 (en) 2002-01-14
WO1999061013A2 (en) 1999-12-02
CZ20004350A3 (cs) 2002-02-13
RU2236220C2 (ru) 2004-09-20
HUP0102550A2 (hu) 2001-10-28
KR100591652B1 (ko) 2006-06-26
EP1079830A1 (en) 2001-03-07
HUP0101894A3 (en) 2002-07-29
IL139826A0 (en) 2002-02-10
US6451829B2 (en) 2002-09-17
MXPA00011422A (es) 2002-12-13
PL345219A1 (en) 2001-12-03
HUP0102128A3 (en) 2002-05-28
CN1721411A (zh) 2006-01-18
WO1999061013A3 (en) 2000-04-06
CA2332985A1 (en) 1999-12-02
IL139827A0 (en) 2002-02-10
HUP0101894A2 (hu) 2002-02-28
NO20005887D0 (no) 2000-11-21
UA67774C2 (uk) 2004-07-15
NO20005887L (no) 2001-01-19
NO20005889D0 (no) 2000-11-21
HUP0102128A2 (hu) 2002-03-28
NZ508416A (en) 2004-01-30
CN1317965A (zh) 2001-10-17
EP1077695A2 (en) 2001-02-28
MXPA00011470A (es) 2002-10-17
WO1999061020A1 (en) 1999-12-02
AU4094299A (en) 1999-12-13
EP1077700A1 (en) 2001-02-28
DE69924607D1 (de) 2005-05-12
US6271390B1 (en) 2001-08-07
US20020010343A1 (en) 2002-01-24
WO1999061019A1 (en) 1999-12-02
CA2332999A1 (en) 1999-12-02
ZA200007754B (en) 2001-08-16
AU754562B2 (en) 2002-11-21
EP1077700B1 (en) 2005-04-06
JP2002516276A (ja) 2002-06-04
BR9910640A (pt) 2001-10-30
ES2241285T3 (es) 2005-10-16
UA67775C2 (uk) 2004-07-15
ZA200007753B (en) 2001-07-18
NO20005888D0 (no) 2000-11-21
PL345560A1 (en) 2001-12-17
BR9910642A (pt) 2001-10-09
HUP0102550A3 (en) 2002-11-28
CN1219510C (zh) 2005-09-21
RU2236221C2 (ru) 2004-09-20
CN1311679A (zh) 2001-09-05
ZA200007752B (en) 2001-12-05
AU4312099A (en) 1999-12-13
NZ508413A (en) 2003-08-29
NO20005889L (no) 2001-01-22
MXPA00011467A (es) 2002-10-17
KR20010030179A (ko) 2001-04-16
CA2332989A1 (en) 1999-12-02
CN1311675A (zh) 2001-09-05
NO20005888L (no) 2001-01-22
JP2002516277A (ja) 2002-06-04
CZ20004351A3 (cs) 2001-10-17
JP2002516274A (ja) 2002-06-04
IL139828A0 (en) 2002-02-10
BR9910641A (pt) 2001-10-02
ATE292465T1 (de) 2005-04-15
AU4197899A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
AU754943B2 (en) Benzimidazole analogs as down-regulators of IgE
US20030100582A1 (en) Benzimidazole compounds for regulating IgE
KR100599906B1 (ko) ＩｇＥ의 조절제로서의 벤즈이미다졸 유도체
US6369091B1 (en) Benzimidazole analogs as down-regulators of IgE
US20030004203A1 (en) Benzimidazole derivatives as modulators of IgE
US7256287B2 (en) Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003277152A1 (en) Phenyl-indole compounds
US20040214821A1 (en) Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6303645B1 (en) Benzimidazole derivatives as modulators of IgE
AU2003201363B2 (en) Benzimidazole analogs as down-regulators of IgE
EP1555020A2 (en) Benzimidazole derivatives as modulators IgE
HK1035326A1 (en) Benzimidazole derivatives as modulators of ige
HK1035326B (en) Benzimidazole derivatives as modulators of ige

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)